Quiero saber acerca de...

Federal Register / Vol. 86, No. 174 / Monday, September 13, 2021 / Notices Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/
PRAMain. Find this particular information collection by selecting Currently under 30-day ReviewOpen for Public Comments or by using the search function.
To obtain copies of a supporting statement and any related forms for the proposed collections summarized in this notice, you may make your request using one of following:
1. Access CMS website address at website address at: https
www.cms.gov/Regulations-andGuidance/Legislation/Paperwork ReductionActof1995/PRA-Listing.html.
FOR FURTHER INFORMATION CONTACT:
William Parham at 410 7864669.
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 PRA
44 U.S.C. 35013520, federal agencies must obtain approval from the Office of Management and Budget OMB for each collection of information they conduct or sponsor. The term collection of information is defined in 44 U.S.C.
35023 and 5 CFR 1320.3c and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506c2A of the PRA 44 U.S.C.
3506c2A requires federal agencies to publish a 30-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, CMS is publishing this notice that summarizes the following proposed collections of information for public comment:
1. Type of Information Collection Request: Revision of a currently approved collection; Title of Information Collection: State Childrens Health Insurance Program and Supporting Regulations; Use: States must submit title XXI plans and amendments for approval by the Secretary. We use the plan and its subsequent amendments to determine if the state has met the requirements of title XXI. Information provided in the state plan, state plan amendments, and from the other information we are collecting will be used by advocacy groups, beneficiaries, applicants, other governmental agencies, providers groups, research organizations, health care corporations, health care consultants. States will use the
lotter on DSK11XQN23PROD with NOTICES1

ADDRESSES:

VerDate Sep<11>2014

17:39 Sep 10, 2021

Jkt 253001

information collected to assess state plan performance, health outcomes and an evaluation of the amount of substitution of private coverage that occurs as a result of the subsidies and the effect of the subsidies on access to coverage.
This iteration proposes to: Remove certain reporting requirements, revise the information collection instrument, and revise reporting instructions. We are also proposing to change the respondents occupation and hourly wage, adjust the number of respondents, and adjust the number of enrollees by using more recent data. Form Number:
CMSR308 OMB control number:
09380841; Frequency: Yearly, Once, and Occasionally; Affected Public: State, Local, or Tribal Governments; Number of Respondents: 51; Total Annual Responses: 9,677,272; Total Annual Hours: 485,940. For policy questions regarding this collection contact Cassie Lagorio at 4107864554.
Dated: September 7, 2021.
William N. Parham, III, Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs.
FR Doc. 202119599 Filed 91021; 8:45 am BILLING CODE 412001P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration Docket No. FDA2021N0008

Blood Products Advisory Committee;
Notice of Meeting AGENCY:

Food and Drug Administration,
HHS.
ACTION:

Notice.

The Food and Drug Administration FDA or Agency announces a forthcoming public advisory committee meeting of the Blood Products Advisory Committee.
The general function of the committee is to provide advice and recommendations to the Agency on FDAs regulatory issues. Members will participate via teleconference. At least one portion of the meeting will be closed to the public.
DATES: The meeting will be held on November 4, 2021, from 9:30 a.m. to 5:20 p.m. Eastern Time.
ADDRESSES: Please note that due to the impact of the COVID19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform. The online web conference meeting will be available at the following link on the SUMMARY:

PO 00000

Frm 00015

Fmt 4703

Sfmt 4703

50885

day of the meeting: https youtu.be/
2Xz4YzkwNDs.
FOR FURTHER INFORMATION CONTACT:
Christina Vert or Joanne Lipkind, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 71, Rm.
6268, Silver Spring, MD 209930002, 2404028054, Christina.Vert@
fda.hhs.gov, or 2404028106, Joanne.Lipkind@fda.hhs.gov, respectively, or FDA Advisory Committee Information Line, 1800
7418138 3014430572 in the Washington, DC area. A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.
Therefore, you should always check the Agencys website at https
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. On November 4, 2021, for Topic I, the committee will meet in open session to hear an overview of the research programs of the Plasma Derivatives Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research CBER. For Topic II, the committee will meet in open session to hear an overview of the research programs of the Laboratory of Cellular Hematology, Division of Blood Components and Devices, Office of Blood Research and Review OBRR, CBER. For Topic III, the committee will meet in open session to hear an overview of the research programs of the Laboratory of Emerging Pathogens, Division of Emerging &
Transfusion Transmitted Diseases, OBRR, CBER. After the open sessions, the meeting will be closed to the public for committee deliberations.
FDA intends to make background material available to the public no later than 2 business days before the meeting.
If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDAs website after the meeting. Background material is
E:FRFM13SEN1.SGM

13SEN1